Stonepine Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Stonepine Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,176,344	Closed	-$2.38M	–	23
2022 Q2	$2.38M	Sell	1,176,344 -20,901	-2%	-$48.8K	1.11%	17
2022 Q1	$2.99M	Buy	1,197,245 +2,575	+0.2%	+$7.3K	1.24%	17
2021 Q4	$4.46M	Buy	1,194,670 +1,028,895	+621%	+$4.04M	2.04%	12
2021 Q3	$665K	Sell	165,775 -254,167	-61%	-$973K	0.3%	25
2021 Q2	$1.87M	Sell	419,942 -603,467	-59%	-$4.95M	0.98%	21
2021 Q1	$9.36M	Buy	1,023,409 +73,409	+8%	+$686K	5.06%	8
2020 Q4	$9.63M	Sell	950,000 -196,470	-17%	-$1.07M	7.37%	3
2020 Q3	$4.86M	Buy	1,146,470 +478,040	+72%	+$2.53M	5.06%	6
2020 Q2	$4.63M	Sell	668,430 -156,867	-19%	-$700K	8.97%	4
2020 Q1	$2.31M	Buy	+825,297	New	+$3.41M	2.44%	20
2019 Q4	–	Sell	-13,705	Closed	-$28K	–	24
2019 Q3	$28K	Buy	+13,705	New	+$44.3K	0.03%	26
2019 Q2	–	Sell	-250,000	Closed	-$1.14M	–	27
2019 Q1	$1.14M	Buy	+250,000	New	+$902K	0.65%	27

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Stonepine Capital Management's DMAC Position: Q3 2022 in Review

Stonepine Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q3 2022, closing a stake of 1,176,344 shares — an estimated $2.38M sold.

Stonepine Capital Management first reported a position in DMAC in Q1 2019 and held it in 12 quarters. The position peaked at $9.63M in Q4 2020. 26 funds tracked by Wall St. Rank hold DMAC as of Q3 2022.

Stonepine Capital Management reported no remaining DiaMedica Therapeutics position as of Q3 2022 after selling out during the quarter.
Stonepine Capital Management sold 1,176,344 DiaMedica Therapeutics shares in Q3 2022, an estimated $2.38M.
Stonepine Capital Management first reported a position in DiaMedica Therapeutics in Q1 2019 and held it in 12 quarters.
Stonepine Capital Management's DiaMedica Therapeutics position peaked at $9.63M in Q4 2020.
26 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2022.

Based on Stonepine Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.